A Phase IB Clinical Study Of The Farnesyltransferase Inhibitor SCH 66336 [lonafarnib] And Gemcitabine In Patients With Resectable Primary Liver Neoplasms.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 30 Apr 2012
At a glance
- Drugs Lonafarnib (Primary) ; Gemcitabine
- Indications Liver cancer
- Focus Therapeutic Use
- 13 Apr 2011 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 22 Jul 2010 Actual initiation date (Oct 1998) added as reported by ClinicalTrials.gov.
- 22 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.